尿素循环障碍治疗市场 - 全球产业规模、份额、趋势、机会和预测（按酵素缺乏类型、治疗类型、给药途径、分销管道、地区和竞争格局划分），2021-2031年

全球尿素循环障碍治疗市场预计将从2025年的5.6016亿美元成长到2031年的6.8778亿美元，复合年增长率（CAGR）为3.48%。该市场主要针对罕见遗传性疾病的治疗，这些疾病会导致体内氮代谢功能受损，造成危险的氨积累。主要治疗方法包括脱氮、胺基酸替代疗法和酵素替代疗法，旨在清除氨并恢復代谢稳定性。市场成长的主要驱动力是新生儿筛检和先进基因检测的广泛应用，这使得快速且准确的诊断成为可能。根据美国国家尿素循环障碍基金会（NUCDF）2024年的报告，这些疾病的盛行率估计约为每35,000名新生儿中就有1例，这凸显了需要终身护理的庞大患者群体的存在。

儘管临床治疗取得了进展，但由于孤儿药价格高昂以及核准流程复杂，市场仍面临许多障碍。这些经济和程序上的障碍会严重限制患者获得必要治疗的机会，对医疗基础设施造成沉重的经济负担，并可能阻碍资源匮乏地区更广泛的市场接受度。因此，儘管科学不断进步，经济因素仍然是公平获得治疗和更广泛市场应用的一大挑战。

市场驱动因素

基因疗法和基于mRNA的干预技术的兴起正在改变全球尿素循环障碍治疗市场，使其不再局限于症状管理，而是有望实现治癒。这些先进技术旨在恢復肝酵素功能，从而使氨水平正常化，并预防神经认知功能下降，而无需终身饮食限製或肝臟移植。近期临床数据支持了这些基因药物的疗效，也为这项技术进步提供了佐证。例如，2025年6月，Arcturus Therapeutics公布了其mRNA候选药物ARCT-810的II期中期数据，结果显示，在鸟胺酸氨甲酰基转移酶缺乏症患者中，第五次给药后相对尿素功能（RUF）显着改善了43.7%。这推动了针对潜在遗传病因的生物製药的投资增加，并提升了市场预期。

与这些技术创新同步，一系列新型疗法的研发管线和正在进行的临床试验正在迅速扩大支持疾病长期管理的证据基础。製药公司优先考虑产生持续的安全性和有效性数据，以促进监管部门的核准和更广泛的患者群体获得市场准入。 2025年8月，Imedica Pharma发表了两项国际研究的长期追踪结果，这两项研究共纳入45名患者，结果显示Lorgys（pegdilarginase）在五年内可提供持续的临床效益，包括改善运动功能。然而，将这些特殊疗法推向市场仍面临挑战。 2025年11月，Zebra Therapeutics指出，自Olprava上市以来，该公司仅收到30份处方登记表，凸显了在超罕见疾病领域，患者识别和市场渗透方面仍然面临的挑战。

市场挑战

全球尿素循环障碍治疗市场面临巨大的成长抑制因素，孤儿药价格高昂和法规环境复杂是限制因素，严重阻碍了患者获得治疗和商业性永续性。脱氮和酵素替代疗法的高昂成本常常引发保险公司和医疗支付方的抵制，这些挑战阻碍了市场扩张。当高昂的成本导致报销政策限制时，资源匮乏地区的患者将无力承担必要的终身治疗方法，从而导致患者群体萎缩，并抑制了生产商的产生收入。

此外，罕见疾病药物研发所需的严格临床试验通讯协定增加了研发者的财务风险，迫使他们提高定价以回收投资。由于目标患者群有限，难以回收研发成本，这种经济压力尤其突出。根据美国药品研究与製造商协会（PhRMA）预测，到2024年，一种新药上市的平均成本约为26亿美元，研发週期通常超过10年。如此庞大的资金需求阻碍了新进业者进入该市场，并减缓了全球尿素循环障碍治疗市场创新治疗方法的普及。

市场趋势

由于传统脱氮剂口感不佳，导致患者治疗顺从性差，因此，市场格局正因新型掩味口服製剂的研发而重塑。这一趋势包括无味液体製剂及其学名药的商业化，显着减轻了患者日常饮食管理的负担。这些创新对于维持慢性病治疗的依从性至关重要，同时也透过提供更经济实惠的选择，促进了市场扩张。 2025年10月，Endo宣布在美国推出首个获得FDA核准的RAVICTI（苯丁酸甘油酯）非专利口服液体製剂，使更多仅靠饮食难以控制血氨水平的患者能够获得这种重要的氮结合疗法。

同时，专注于罕见疾病药物创新的策略联盟正透过生物技术公司与患者权益倡导组织之间的合作，弥合诊断方面的差距。这些合作旨在发现未被充分诊断​​的患者群体，例如晚髮型病例和误诊婴儿，从而扩大符合特殊治疗条件的用户层。透过利用区域网络，这些联盟提高了公众对疾病的认识，鼓励及时进行代谢检测，并在降低高氨血症相关死亡率方面发挥至关重要的作用。为了强调这一紧迫性，美国国家尿素循环障碍基金会于2025年10月宣布，高达20%的婴儿猝死症候群（SIDS）病例可能由未确诊的先天性筛检缺陷引起，并呼吁业界广泛合作，对这些疾病进行筛检。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球尿素循环障碍治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 酵素缺乏类型（氨甲酰磷酸合成酶 (CPS1)、N-麸胺酸合成酶 (NAGS)、鸟氨酸转氨甲酰酶 (OTC 缺乏症)、精氨琥珀酸合成酶 (AS)、精氨琥珀酸解离酶(AL 或 ASA解离酶)、精氨酸酶 (AG)）
  • 依治疗类型（胺基酸製剂、苯丁酸、苯甲酸钠、其他）
  • 依给药途径（口服与静脉注射）
  • 按分销管道（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美尿素循环障碍治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

7. 欧洲尿素循环障碍治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区尿素循环障碍治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲尿素循环障碍治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲尿素循环障碍治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球尿素循环障碍治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bausch Health Companies Inc.
• Recordati Rare Diseases
• Eurocept Pharmaceuticals Holding
• Acer Therapeutics
• Ultragenyx Pharmaceutical
• Aeglea BioTherapeutics
• Arcturus Therapeutics, Inc.
• Orpharma Pty Ltd.
• Selecta Biosciences, Inc.
• Abbott Laboratories, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Urea Cycle Disorders Treatment Market is projected to expand from USD 560.16 Million in 2025 to USD 687.78 Million by 2031, registering a compound annual growth rate (CAGR) of 3.48%. This market sector covers therapeutic measures aimed at controlling rare genetic disorders characterized by the body's inability to process nitrogen, leading to dangerous ammonia buildup. Core treatments include nitrogen scavengers, amino acid supplementation, and enzyme replacement therapies intended to aid ammonia removal and reestablish metabolic stability. A primary factor driving market growth is the broad adoption of comprehensive newborn screening and sophisticated genetic testing, which enables prompt and precise diagnosis. As reported by the National Urea Cycle Disorders Foundation in 2024, the prevalence of these conditions was approximately 1 in 35,000 births, highlighting a vital patient group necessitating lifelong care.

Despite clinical progress, the market faces significant hurdles due to the exorbitant costs associated with orphan drugs and the intricate regulatory pathways required for approval. These financial and procedural barriers can severely restrict patient access to essential therapies and place heavy economic strain on healthcare infrastructures, which may impede wider market acceptance in resource-constrained regions. Consequently, economic factors remain a persistent challenge to equitable treatment availability and broader market adoption despite scientific advancements.

Market Driver

The Global Urea Cycle Disorders Treatment Market is undergoing a transformative shift toward potential cures, driven by the rise of gene therapy and mRNA-based interventions, moving beyond mere symptom management. These advanced technologies seek to reinstate functional liver enzyme activity, thereby normalizing ammonia levels and preventing neurocognitive decline without the need for lifelong dietary restrictions or liver transplantation. This technological progress is supported by recent clinical data validating the efficacy of these genetic medicines. For instance, Arcturus Therapeutics reported in June 2025 that interim Phase 2 data for their mRNA candidate, ARCT-810, showed a statistically significant improvement in relative ureagenesis function (RUF) to 43.7% following the fifth dose in patients with ornithine transcarbamylase deficiency, fueling increased investment and market anticipation for biologics targeting the underlying genetic causes.

Alongside these technological innovations, a strong pipeline of new therapeutics and ongoing clinical trials is rapidly broadening the evidence base supporting long-term disease management. Pharmaceutical companies are prioritizing the generation of durable safety and efficacy data to facilitate regulatory approval and market entry for wider patient populations. In August 2025, Immedica Pharma released long-term follow-up results from two international studies involving 45 patients, demonstrating that Loargys (pegzilarginase) offered sustained clinical advantages, such as enhanced mobility, over five years. However, bringing these specialized treatments to market remains difficult; Zevra Therapeutics noted in November 2025 that only 30 prescription enrollment forms had been received for Olpruva since its launch, underscoring the enduring difficulties of patient identification and market penetration within the ultra-rare disease sector.

Market Challenge

The Global Urea Cycle Disorders Treatment Market faces significant growth obstacles due to the high pricing of orphan drugs and a complicated regulatory environment, which create substantial barriers to patient access and commercial sustainability. These challenges impede market expansion because the steep costs of nitrogen scavengers and enzyme replacement therapies frequently result in pushback from insurance providers and healthcare payers. When reimbursement policies are restrictive due to these high expenses, patients in lower-resource settings often cannot afford necessary lifelong treatment regimens, which effectively shrinks the addressable patient base and stalls revenue generation for manufacturers.

Additionally, the strict clinical trial protocols required for rare diseases heighten the financial risks for developers, forcing them to set premium prices to recoup their investments. This economic pressure is particularly acute given the challenge of recovering development costs from a limited target population. According to the Pharmaceutical Research and Manufacturers of America, the average cost to bring a new medicine to market in 2024 was roughly $2.6 billion, with the development timeline often exceeding ten years. This massive capital requirement deters new market entrants and delays the availability of innovative therapies within the Global Urea Cycle Disorders Treatment Market.

Market Trends

The market is being reshaped by the development of taste-masked oral formulations, which address the issue of treatment adherence caused by the unpalatable nature of conventional nitrogen scavengers. This trend involves the commercialization of flavorless, liquid-based agents and their generic counterparts, significantly easing the daily burden of dietary management for patients. These innovations are crucial for maintaining compliance in chronic care while also expanding market reach through more affordable options. In October 2025, Endo announced the launch of the first FDA-approved generic version of RAVICTI (glycerol phenylbutyrate) oral liquid in the United States, thereby increasing access to a vital nitrogen-binding therapy for individuals unable to manage ammonia levels solely through diet.

Concurrently, strategic alliances focused on orphan drug innovation are bridging diagnostic gaps through partnerships between biotechnology firms and patient advocacy groups. These collaborations seek to uncover undiagnosed patient populations, including those with late-onset symptoms or infants previously misdiagnosed, thus expanding the potential user base for specialized therapies. By utilizing community networks, these alliances promote disease awareness initiatives critical for encouraging timely metabolic testing and lowering mortality rates linked to hyperammonemia. Highlighting this urgency, the National Urea Cycle Disorders Foundation stated in October 2025 that up to 20% of sudden infant death syndrome (SIDS) cases might be caused by undiagnosed inborn errors of metabolism, emphasizing the need for broad screening supported by industry cooperation.

Key Market Players

• Bausch Health Companies Inc.
• Recordati Rare Diseases
• Eurocept Pharmaceuticals Holding
• Acer Therapeutics
• Ultragenyx Pharmaceutical
• Aeglea BioTherapeutics
• Arcturus Therapeutics, Inc.
• Orpharma Pty Ltd.
• Selecta Biosciences, Inc.
• Abbott Laboratories, Inc.

Report Scope

In this report, the Global Urea Cycle Disorders Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type

• Carbamyl Phosphate Synthetase (CPS1)
• N-Acetylglutamate Synthetase (NAGS)
• Ornithine Transcarbamylase (OTC Deficiency)
• Argininosuccinic Acid Synthetase (AS)
• Argininosuccinate Lyase (AL or ASA Lyase)
• Arginase (AG)

Urea Cycle Disorders Treatment Market, By Treatment Type

• Amino Acid Formulas
• Phenylbutyrate
• Sodium Benzoate
• Others

Urea Cycle Disorders Treatment Market, By Route of Administration

• Oral v/s Intravenous

Urea Cycle Disorders Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Urea Cycle Disorders Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Urea Cycle Disorders Treatment Market.

Available Customizations:

Global Urea Cycle Disorders Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Urea Cycle Disorders Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS), Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG))
  • 5.2.2. By Treatment Type (Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others)
  • 5.2.3. By Route of Administration (Oral v/s Intravenous)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Urea Cycle Disorders Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Enzyme Deficiency Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Urea Cycle Disorders Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Enzyme Deficiency Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Urea Cycle Disorders Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Enzyme Deficiency Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Urea Cycle Disorders Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Enzyme Deficiency Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Urea Cycle Disorders Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Enzyme Deficiency Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Urea Cycle Disorders Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Enzyme Deficiency Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Urea Cycle Disorders Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Enzyme Deficiency Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Urea Cycle Disorders Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Enzyme Deficiency Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Urea Cycle Disorders Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Enzyme Deficiency Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Urea Cycle Disorders Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Enzyme Deficiency Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Urea Cycle Disorders Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Enzyme Deficiency Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Urea Cycle Disorders Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Enzyme Deficiency Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Urea Cycle Disorders Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Enzyme Deficiency Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Urea Cycle Disorders Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Enzyme Deficiency Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Urea Cycle Disorders Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Enzyme Deficiency Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Urea Cycle Disorders Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Enzyme Deficiency Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Urea Cycle Disorders Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Enzyme Deficiency Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Urea Cycle Disorders Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Enzyme Deficiency Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Urea Cycle Disorders Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Enzyme Deficiency Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Urea Cycle Disorders Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Enzyme Deficiency Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Urea Cycle Disorders Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Enzyme Deficiency Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Urea Cycle Disorders Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Enzyme Deficiency Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Urea Cycle Disorders Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Enzyme Deficiency Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Urea Cycle Disorders Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Enzyme Deficiency Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Urea Cycle Disorders Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bausch Health Companies Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Recordati Rare Diseases
• 15.3. Eurocept Pharmaceuticals Holding
• 15.4. Acer Therapeutics
• 15.5. Ultragenyx Pharmaceutical
• 15.6. Aeglea BioTherapeutics
• 15.7. Arcturus Therapeutics, Inc.
• 15.8. Orpharma Pty Ltd.
• 15.9. Selecta Biosciences, Inc.
• 15.10. Abbott Laboratories, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer